Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

Core Insights - The article discusses the recent updates and financial results of Affimed NV (NASDAQ:AFMD), focusing on its key assets in clinical development: AFM24, acimtamig, and AFM28 [2][4][5] - The upcoming updates on these assets are anticipated to significantly impact the company's valuation, which is currently around $60 million [4][19] - The company is expected to provide updates on acimtamig and AFM24 in the near future, with potential for increased asset value based on positive clinical data [4][16] Financial Overview - As of the latest report, the company has approximately $52.4 million in cash and a burn rate of about $21.58 million, indicating a potential need for capital raising within the next 6-12 months [4][15] - The company is projected to have enough cash to last through the first half of 2025, contingent on achieving certain milestones [15] Asset Analysis - AFM24: Early results in NSCLC show promising outcomes, with 4 of 17 patients responding positively in the wildtype cohort and 4 of 13 in the mutant cohort. Upcoming updates on a larger patient group could be pivotal [6][8] - Acimtamig: The recent update indicated an overall response rate (ORR) of 85.7% in a small cohort for r/r Hodgkin Lymphoma, with expectations for improved results as more data becomes available [9][10] - AFM28: Initial results show a 33% ORR in a small cohort of r/r AML patients, suggesting potential for further development and partnership opportunities [11][13] Strategic Considerations - The company is exploring potential collaborations, particularly for AFM28, which could enhance its market position and financial stability [15][19] - The upcoming ASH meeting in December is expected to provide further insights into the clinical progress of acimtamig and AFM28, which could influence investor sentiment and stock valuation [4][19] Market Potential - The potential market for AFM24 in NSCLC is substantial, with estimates suggesting a multi-billion-dollar revenue opportunity if it proves to be a viable treatment option [16][17] - Acimtamig's peak sales potential is projected to be between $500 million to $1 billion, depending on clinical outcomes and market conditions [16][17] Leadership Changes - The recent appointment of a new CEO is expected to bring changes to the company's strategic direction, which may influence investor confidence and stock performance [19]